No quarterly revenue total was found in MUSTANG BIO, INC.'s SEC filings.
Mustang Bio, Inc. (MBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-964,000
-106.0% vs year-ago quarter
Operating cash flow
$-876,000
-7.1% vs year-ago quarter
Free cash flow
$-2.00M
EPS
$-0.14
-100.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
106.43M
+16.7% vs year-ago quarter
Net cash
$17.27M
Q4 FY2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680048
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.1M | -$1.2M | -$1.1M | -$670,000 | -$624,000 |
| Net income | -$964,000 | -$1.1M | -$955,000 | -$538,000 | -$468,000 |
| Diluted EPS | -$0.14 | -$0.16 | -$0.14 | -$0.08 | -$0.07 |
| Operating cash flow | -$876,000 | -$967,000 | -$1.0M | -$1.7M | -$818,000 |
| Total assets | $14.7M | $15.6M | $16.6M | $17.6M | $19.4M |
| Total liabilities | $8.1M | $8.1M | $8.0M | $8.1M | $9.6M |
| Stockholders' equity | $6.6M | $7.5M | $8.6M | $9.5M | $9.8M |
| Cash and investments | $14.3M | $15.2M | $16.3M | $17.3M | $19.0M |
| Total debt | — | — | — | $0 | $0 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 13, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Listing notice
|
Apr 17, 2026 | Apr 15, 2026 |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
All 405 Mustang Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.